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Use of complementary medicines and therapies (CAM) and modification of lifestyle factors such as physical activity and exercise,
and diet are being increasingly considered as potential therapeutic options for anxiety disorders. The objective of this metareview
was to examine evidence across a broad range of CAM and lifestyle interventions in the treatment of anxiety disorders. In early
2012 we conducted a literature search of PubMed, Scopus, CINAHL, Web of Science, PsycInfo, and the Cochrane Library, for key
studies, systematic reviews, and metaanalyses in the area. Our review found that in respect to treatment of generalized anxiety
or specific anxiety disorders, CAM evidence revealed support for the herbal medicine Kava. One isolated study shows benefit for
naturopathic medicine, whereas acupuncture, yoga, and Tai chi have tentative supportive evidence, which is hampered by overall
poor methodology. The breadth of evidence does not support homeopathy for treating anxiety. Strong support exists for lifestyle
modifications including adoption of moderate exercise and mindfulness meditation, whereas dietary improvement, avoidance of
caffeine, alcohol, and nicotine offer encouraging preliminary data. In conclusion, certain lifestyle modifications and some CAMs
may provide a beneficial role in the management of anxiety disorders.
1. Introduction
Anxiety disorders as a collective entity are pervasive and
include discrete diagnoses of generalized anxiety disorder
(GAD), social phobia (SP), obsessive compulsive disorder
(OCD), panic disorder (PD), and post traumatic stress
disorder (PTSD) [1]. Anxiety disorders present with a
marked element of psychological tension and distress and
are accompanied by a range of somatic symptoms such as
palpitations, shortness of breath, dizziness, hyperthermia,
and digestive disturbance [1]. Lifetime prevalence rates of
anxiety disorders are approximately 3%–6% for GAD, 4%–
6% for SP, 1%–3% for OCD, 1%-2% for PTSD, and 1%–3%
for PD [2, 3].
There are currently various effective psychological
therapies and pharmacological treatments available for
anxiety disorders. The recommended first-line treatment
strategies for most anxiety disorders include antidepressants
and/or cognitive behavioural therapy (CBT) [4]. In respect
to pharmacotherapies, there is a good evidence base for both
short-term and long-term treatment with paroxetine (espe-
cially for PD), escitalopram, venlafaxine extended release,
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Table 1: Domains and individual interventions reviewed.
Lifestyle Herbalmedicine Nutrient Mind-body CAM modality
Physical activity Kava Multi-vitamins Meditation Naturopathic medicine
Exercise Passion flower Omega-3 Mindfulness Massage
Diet Scullcap Magnesium Yoga Acupuncture
Caffeine Bacopa Inositol Tai chi Homeopathy
Nicotine Ginkgo Aromatherapy
Alcohol Lemon balm
St John’s wort
and duloxetine [5]. Despite their modest effectiveness
(effect size for GAD of 0.38 for selective serotonin reuptake
inhibitors: SSRIs) [6], antidepressants have significant
limitations, including a relatively slow onset of action and
time to maximal effect, and a number of possible side effects,
including initial increase in anxiety in the short-term (often
problematic for patient compliance), and sexual side effects,
which affect over 50% of users [7] in the longerterm.
Benzodiazepines have established efficacy for many
anxiety disorders [5] but also numerous limitations. They
can be very helpful for ameliorating symptoms rapidly and
are usually prescribed for short-term use. However, this
recommendation can be very difficult to institute due to
potential reliance for symptom relief. Benzodiazepines are no
longer recommended beyond short-term use due to potential
for abuse, the development of dependence, significant risks
when combined with alcohol, and possible long-term cogni-
tive effects [8]. There have been recent positive randomised
controlled trials (RCTs) with pregabalin, however, its indica-
tion for GAD in Europe has not yet been replicated by other
regulatory authorities [5]. Psychological techniques are also
effective first-line interventions for anxiety [9]. In particular,
there is a body of evidence for CBT that usually involves
psychoeducation, relaxation training, cognitive restructuring
and behavioural aspects [4]. Despite effectiveness, some
patients are not suited or motivated for face-to-face CBT,
access may be an issue, and the cost can be prohibitive [10].
Approximately 50%–65% of patients with anxiety disor-
ders benefit from CBT or antidepressants [11, 12]. However,
many patients continue to suffer significant symptoms
despite treatment, underlining the need for further options
or adjuncts to current conventional treatments. Further-
more, anxiety disorders are often under-treated [13], moti-
vating patients to seek different treatment approaches such
as complementary and alternative medicine (CAM). Non-
conventional treatments are commonly used for anxiety,
with CAM, lifestyle modifications, and self-help techniques
often used in concert with pharmacotherapies and psy-
chological techniques [14, 15]. Complementary medicines
consist of herbal and nutrient products, while complemen-
tary therapies include interventions such as acupuncture,
naturopathy, chiropractics, and homeopathy [16]. Self-
help techniques include Tai chi, yoga, and meditation,
while lifestyle modifications may involve the employment
of dietary alteration, exercise, and the minimisation of
substances such as alcohol, caffeine, and tobacco. CAM use
for people with anxiety disorders is prevalent with a US
cross-sectional and longitudinal survey demonstrating 43%
of individuals with DSM-IV criteria for GAD, PD, SP, or
PTSD use a variety of CAM treatments [17]. Use of CAMwas
associated with a diagnosis of GAD, older age, greater educa-
tion, and having two or more chronic medical conditions.
While previous reviews have explored the use of CAM
or self-help techniques in the management of anxiety [14,
18, 19], to date no review has comprehensively assessed
this broad area across all major clinical anxiety disorders
to provide an integrated assessment of current evidence.
Thus, this narrative paper examines the current evidence
base for nonconventional treatments of anxiety disorders,
including discussion of their neurobiological underpinnings,
and provides considerations for their potential integration
into clinical practice.
2. Methods
A range of databases (PubMed, Scopus, CINAHL, Web of
Science and PsycINFO, and The Cochrane Library) were
searched during early 2012. Each author contributed to
an area of their respective expertise (D. Mischoulon: CAM
therapies; J. Sarris and M. P. Pase: CAM natural products
(i.e., herbal and nutrient supplements); F. N. Jacka and
S. Moylan: diet and exercise; D. A. Camfield: meditative
techniques; M. Berk lifestyle modification; I. Schweitzer:
conventional pharmacotherapies). The literature search of
key interventions for treating general anxiety, and diagnosed
clinical anxiety disorders (GAD, PD, SP, OCD, and PTSD)
focused on (1) CAM natural products (nutraceuticals) (2)
CAM modalities (3) Meditation and mindfulness techniques
(4) Lifestyle modification using physical activity, exercise,
diet, and restriction of caffeine, alcohol, and nicotine
(see Table 1). As a narrative inclusive “metareview” was
conducted, the studies included a range of evidence (from
epidemiological to human clinical studies, and metaanalyses
and systematic reviews). Key studies, reviews, and metaanal-
yses were focused on. Further review of the literature was
undertaken to study the posited mechanisms of action of
these interventions. The literature reviewed was restricted to
papers written in English. The term “significant” was applied
to results with a P value of <0.05.
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3. Results
3.1. Complementary Therapies
3.1.1. Overview. There are several complementary therapy
modalities touted as having potential benefit in the treatment
of anxiety, including interventions such as acupuncture,
massage, naturopathy, chiropractics, and homeopathy [16].
Regulation of these practices and their practitioners vary
depending on jurisdiction, and if clinicians are referring
patients for these treatments, several considerations should
be recognised, including evidence for the modality, cost of
the treatment, and the training and qualification of the
therapist.
3.1.2. Naturopathic Medicine. Naturopathic practitioners
seek to improve health by assisting the body’s innate
capacity to recover from illness [20]. Practitioners typically
employ a combination of many CAM therapies, including
herbal and nutritional supplementation, and dietary and
lifestyle recommendations, andmay additionally incorporate
acupuncture or homeopathy. Only one study has been per-
formed with regard to naturopathic medicine (naturopathy)
in the area of anxiety disorders, although another naturalistic
observational study is currently underway [21].
A double-blind RCT by Cooley and colleagues [22]
compared a naturopathic therapy (NT) protocol, including
the herbal medicine Ashwagandha (Withania somnifera)
300mg twice daily, dietary counseling, breathing relaxation
techniques, and a standard multivitamin. Eighty-seven sub-
jects with moderate to severe anxiety of longer than six weeks
were recruited. The control group received a standardized
psychotherapy intervention (PT), matched deep breathing
relaxation techniques, and placebo pill supplement over 12
weeks. Final Beck Anxiety Inventory (BAI) scores decreased
significantly in both groups, by 56.5% in the NT group
and 30.5% in the PT group, with a highly significant
advantage for the NT group compared to PT group. The NT
group also had significantly greater clinical benefit in mental
health, concentration, fatigue, social functioning, vitality,
and overall quality of life. No serious adverse reactions were
reported in either group. The study, while enlightening,
was limited by a small sample size, and utilisation of
comprehensive treatment packages, making it difficult to
assess the benefit of any particular component. Additionally,
Naturopaths frequently apply complex personalized herbal
and nutritional formulations in treatment protocols, and
thus the standardized intervention does not reflect normal
practice. The results however are encouraging and endorse
further research.
3.1.3. Massage Therapy. Therapeutic massage is one of the
most popular CAM treatments for anxiety, but has had
few rigorous evaluations for diagnosed anxiety disorders.
A recent study by Sherman and colleagues [23] assessed
the effectiveness of massage for treatment of GAD. The
investigators randomised 68 patients with GAD to ther-
apeutic massage, thermotherapy (the application of heat
to the body), or relaxation-room therapy for 12 weeks
(total 10 sessions). Changes in various outcome measures,
such as the Hamilton Anxiety Rating Scale (HAM-A), were
assessed at the conclusion of the 12 weeks and also after
six months of additional followup. All three treatment
groups had significant improvement on the HAM-A after 12
weeks and maintained their gains after 26 weeks. However,
no significant differences were found between groups. The
authors concluded that all three treatment arms showed
some clinically significant improvements, perhaps due to a
generalized relaxation response rather than any individual
characteristics of the three treatments. In fact, given the
lower expense of the relaxation-room, the authors suggested
that this particular intervention might prove the most cost-
effective for GAD patients who are interested in CAM [23].
Other investigations have compared CBT against aro-
matherapy massage (AM) for treating symptoms of anxiety
or depression in cancer patients. In a sole comparison of
these two interventions, Serfaty and colleagues [24] recruited
39 cancer patients with anxiety and/or depression assessed
on the Hospital Anxiety Depression Scale (HADS). Subjects
were randomised to treatment as usual (TAU) plus up to
eight sessions of AM or CBT over three months. AM proved
the more acceptable therapy based on sessions attended,
and both treatments were significantly effective based on the
Profile of Mood States (in respect to total mood, depression,
and anxiety scores). CBT had a trend to an advantage in
depression but not in anxiety.
Black and colleagues [25] performed the first controlled
study of chair massage for anxiety in 82 inpatients with-
drawing from alcohol, cocaine, and opiates. Patients were
randomised to three days of chair massage or a relaxation
control condition. Standard counseling and pharmacologic
management were offered concurrently to all patients.
Spielberger State-Trait Anxiety Inventory (STAI) scores were
reduced for both interventions, with a significant advantage
for chair massage.
In summary, preliminary results for massage therapy
suggest benefit in various different patient populations and
contexts, but results are not conclusive, nor commonly
employ a clinical population, while comparisons with
control interventions have often not suggested significant
differential effects. Additional research will be necessary to
characterize their place in anxiety disorder treatment.
3.1.4. Acupuncture. Acupuncture is a very popular CAM
intervention that, unlike the previously mentioned interven-
tions, has a more substantive body of clinical trial evidence
regarding its efficacy and safety in the treatment of anxiety
and depression. A recent review by Pilkington et al. [26]
identified 10 randomized and two nonrandomised clinical
trials of acupuncture for generalised anxiety or anxiety
disorders. Among the RCTs, four were in patients with
GAD or anxiety neurosis, and six in patients with acute
perioperative anxiety.
Analysis of the studies was hampered by common
problems encountered when interpreting the acupuncture
literature in general. These include between-trial variation
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in acupuncture protocols and specific points used.
Furthermore, different studies used a variety of control
interventions, including behavioral desensitisation, sham
acupuncture with nonspecific points, biofeedback, and drug
therapy. The authors were rightfully suspicious of some of
the reported “cure rates” that they described as “unrealisti-
cally high”. Acupuncture appeared to be comparable in effi-
cacy to drug therapy, but this similarity could be explained by
the small sample sizes leading to underpowering of studies,
limiting the ability to detect a difference between treatments.
Other limitations included the mixing of diagnoses in the
samples, for example, anxiety disorder and depression.
Regarding studies for specific DSM-IV diagnoses,
Pilkington and colleagues [26] identified 3 trials specifically
on GAD. These trials were all of short duration (four to six
weeks) and compared acupuncture against pharmacother-
apy. Similar efficacy was found for both interventions, but
small sample sizes limited the generalisability of the findings.
Very few trials in other anxiety disorders such as OCD and
PTSD have also been published, but due to design flaws
do not support solid recommendations about potential
efficacy. In summary, acupuncture appears effective in
short-term use for anxiety symptoms, but we cannot yet
make clear recommendations for specific clinical anxiety
disorders. Adjunctive therapy studies are lacking, which
is unfortunate given that acupuncture is generally well
tolerated and does not appear to cause adverse interactions
with pharmacological therapies [27].
Acupuncture has been documented to interact with
opioid pathways, and interventions which modify these
pathways have been shown to have potential mood
modulatory activity [28, 29]. Other potential mechanisms of
action that may induce anxiolysis include increased release
of serotonin and norepinephrine, and cortisol modulation
[30]. Examination of biological mechanisms of acupuncture
and massage therapy, including measurements of neuro-
transmitters and immune biomarkers has been conducted
in the area of depression [26, 31], although specific research
into the underpinning neurobiological effects of these
interventions to treat anxiety has not yet been explored.
3.1.5. Homeopathy. The practice of homeopathy (use of
preparations consisting of highly diluted substances) has its
roots in the 1800s in Germany where it was used to treat
a range of illnesses and health disorders [16]. A systematic
review by Pilkington and colleagues [32] identified eight
RCTs using homeopathy to treat anxiety. Results revealed
that the benefit of homeopathy in generalised anxiety and
anxiety disorders is unable to be determined, as the identified
studies all exhibited significant methodological issues (e.g.,
small samples, lack of control group). Reported adverse
effects appear to be limited to “remedy reactions” and
included temporary worsening or reappearance of minor
symptoms. Another stricter systematic review by Davidson
et al. [33] of homeopathy in psychiatry, found that for
four of five studies for anxiety (two on GAD), homeopathy
was not superior to placebo. An example of an RCT using
homeopathy to treat anxiety was conducted by Bonne and
colleagues [34]. Forty-four patients with diagnosed GAD
participated in a 10-week RCT of individually tailored
homeopathic remedy. While significant improvement in
most measures, including HAM-A, was observed in both the
active treatment and placebo groups, no difference was found
between groups. In summary, on the basis of the current
literature it is not possible to provide support for the use of
homeopathy for treatment of anxiety disorders.
3.1.6. Conclusions. At this time there is preliminary evidence
for CAM therapies including acupuncture, massage, and
naturopathy in the treatment of anxiety disorders; while
homeopathy is not supported by clinical evidence. No studies
identified assessed chiropractics or osteopathy in treating
anxiety disorders. Thus, in the absence of conclusive studies,
clinicians should prescribe these treatments with caution as
their efficacy is not as well characterised as more standard
therapies.
3.2. Nutraceuticals (Herbal and Nutritional Medicine)
3.2.1. Overview. Over the past 25 years, there has been
increasing interest in the use of nutraceuticals (herbal or
nutritional medicines) for the treatment of anxiety disorders,
with numerous human clinical trials emerging in the area
[19, 35, 36]. At present, the clinical evidence for herbal
medicines, nutrients, and aromatherapy in the treatment of
anxiety varies greatly in respect to methodological quality
(see Table 2). Considerations when referring or prescribing
nutraceuticals involve the knowledge of potential drug
interactions (e.g., with Hypericum perforatum (St John’s
wort) [37]), the additional cost of these supplements,
and most importantly, concern over quality issues [38].
While some nutraceutical companies provide researched,
standardised products, manufactured to a pharmaceutical
standard, such confidence cannot be extended to many
products, thus clinicians need to be mindful that quality and
safety are paramount when integrating nutraceuticals into
the therapeutic domain.
3.2.2. Clinical Evidence for Herbal Medicines. The most
researched herbal medicine in the treatment of anxiety is
Piper methysticum (Kava); a perennial plant native to various
regions of the South Pacific [62]. The roots of the Kava
plant are traditionally prepared as a water-based beverage
for its medicinal properties and psychotropic effects [63].
In 2003, a Cochrane review evaluated the effectiveness of
Kava in treating anxiety [42]. Out of 12 RCTs that satisfied
the inclusion criteria, seven used the HAM-A and were
included in the metaanalysis. The pooled analysis found
Kava to be effective in reducing the HAM-A total score
relative to placebo (weighted mean difference = 3.9, n = 380).
Another pooled analysis of six studies found an effect size
of 1.1 (Cohen’s d) in favour of Kava reducing HAM-A score
over placebo [64]. Those studies not included in the pooled
analysis were generally congruent with this result. A further
metaanalysis of six RCTs reported that a standardised Kava
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extract (WS1490) was effective in significantly improving
anxiety relative to placebo (by 5.94 points on the HAM-A)
further supporting the anxiolytic effects of Kava [43]. The
anxiolytic properties of Kava appear to be due to a collective
group of compounds called kavalactones [65]. Amongst
numerous mechanisms, kavalactones appear to modulate
calcium and sodium channels [66], modify binding of
ligands to GABA receptors [67] and inhibit noradrenaline
uptake [68].
Despite evidence of efficacy, support for the use of
Kava has been blunted by ongoing safety concerns following
numerous reports of liver toxicity [69]. As discussed in detail
elsewhere [64], various factors such as the manufacturing
quality, plant part of Kava used, the method of extraction,
and the dose are potential in factors that affect the safety
of Kava [70]. Interactions with alcohol and pharmaceutical
medications should also be considered.
Limited evidence suggests that Bacopamonnieri (Bacopa)
[71] and Ginkgo biloba (Ginkgo) [35], both used for their
cognitive enhancing effects, may have anxiolytic properties
in humans. Although Ayurvedic writings document Bacopa
in the treatment of anxiety [72], double-blind RCTs inves-
tigating effects of Bacopa on anxiety are scarce. In one
study, where cognition was the primary outcome, 300mg
of standardised Bacopa extract daily for three months in
46 healthy volunteers was found to reduce State anxiety
relative to placebo [39]. One double-blind RCT investigated
the effects of Ginkgo extract EGb 761 on anxiety [41], using
the HAM-A as the primary outcome measure in 107 patients
with GAD or adjustment disorder with anxious mood. After
four weeks of supplementation both a high (480mg/day)
and low dose (240mg/day) of EGb 761 significantly reduced
anxiety compared to placebo in a dose-dependent fashion.
Commonly considered an anti-depressant, the anxiolytic
effects of St John’s wort were investigated in a double-blind
multicentre RCT using a cohort of 324 outpatients with mild
to moderate depression. Twice daily supplementation with
250mg of St John’s wort, relative to 75mg of imipramine,
significantly improved scores on the HAM-A somatisation
subscale [73] over a period of six weeks. A further 6-week
multicentre double-blinded RCT reported that St John’s wort
(600mg/day) significantly improved various subscales on the
HAM-A in a cohort of 151 outpatients with somatoform
disorders [51]. However, studies exploring the use of St
John’s wort in specific anxiety disorders have not produced
positive results. For example, two smaller double-blind RCTs
have not supported its use (both trials used a flexible dose
of 600–1800mg extract daily over 12 weeks) in reducing the
symptoms of OCD [49] or SP [50]. Due to this, St John’s
wort cannot be recommended as an anxiolytic for use in any
anxiety disorder.
Limited evidence exists for an anxiolytic effect of Scutel-
laria lateriflora (Scullcap) and Passiflora incarnata (Passion
flower), both of which have traditionally been used in the
Americas as calming agents [74]. Following acute admin-
istration, one small study reported that Scullcap reduced
anxiety relative to placebo in a dose-dependent fashion [48],
however, the methodology was weak and the results were
communicated poorly. Building upon promising preclinical
research [75], Akhondzedah et al. [47] reported that 45 drops
of randomised Passion flower extract was comparable to
oxazepam in reducing anxiety in 36 patients with GAD. Two
acute double-blind RCTs (samples of 60 participants) have
reported that 500mg of the herbal medicine significantly
reduced anxiety associated with surgery relative to placebo
[46, 76]. Importantly, no negative interactions with anesthe-
sia and surgical outcomes were observed.
A single double-blind RCT has assessed the use of
Matricaria recutita (Chamomile) in the treatment of GAD
[40]. Following eight weeks of treatment in 57 patients,
Chamomile was found to have a modest effect on reducing
anxiety (HAM-A scores) relative to placebo. Adverse events
were not different between the placebo and treatment
groups. Several small double-blind RCTs suggest that Melissa
officinalis (Lemon balm) increases self-rated calmness acutely
in healthy participants [44, 45]. Interestingly, all three of
these double-blind studies reported significant effects on
self-rated calmness with different dosages of Lemon balm
(ranging from 300–1600mg). The effects of Lemon balm
have yet to be investigated in clinical samples.
Aromatherapy (the practice of prescribing isolated
volatile oils from plants via inhalation, massage, or internal
use) is one of the most widely used CAMs in the treatment
of anxiety. A recent systematic review concluded that, across
the 16 studies, aromatherapy was generally safe and effective
in reducing anxiety symptoms [61]. The review reported that
those with higher levels of anxiety appeared to respond better
to aromatherapy than those with mild anxiety. However, the
review noted that many of the studies were of questionable
quality and study cohorts were heterogeneous, comprising
participants with dementia, cancer, and also healthy volun-
teers.
3.2.3. Clinical Evidence of Nutrients. At present, there is
little evidence to support the anxiolytic effects of nutrient
supplementation for treatment ofmost anxiety disorders (see
Table 2). One large double-blind RCT (n = 264) reported
that supplementation with magnesium, when combined in
a herbal formula, decreased anxiety in patients with mild
to moderate generalised anxiety over three months relative
to placebo [77]. In relatively healthy samples, multinutrient
therapy has been shown to have no effect on state anxiety (n =
205) over 12 months [57]or self rated calmness following 28
days (n = 198) [56] and 33 days (n = 215) [55] of treatment.
However, while approximately one month of multinutrient
supplementation reduced anxiety relative to placebo across
88 healthy males [52] and 44 women with premenstrual
symptoms [53], a further study reported no beneficial
effect of multinutrient therapy on anxiety in participants in
aged care following eight weeks of supplementation [54].
In healthy participants (n = 108), one double-blind RCT
reported that a week of amino acid treatment (2.64 g L-
lysine and 2.64 g L-arginine per day) decreased stress-related
anxiety [78].
Despite a lack of evidence for nutrient supplementation
in other anxiety disorders, evidence does suggest that
inositol may have a potential role in ameliorating panic. In
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21 patients with diagnosed PD with or without agoraphobia,
12 g/day of inositol was shown to quell the frequency and
severity of panic attacks and the severity of agoraphobia
in a double-blind four week cross-over trial [58]. A
later small trial involving 20 participants reported that
Inositol (18 g/day for one month) was more effective than
fluvoxamine (250mg/day for one month) in reducing weekly
panic attacks [60]. In 13 patients with OCD, 18 g/day of
Inositol reduced OCD symptoms in a six week cross-over
trial [59], however other studies have revealed equivocal
effects to placebo [79].
3.2.4. Mechanisms of Action. The proposed pharmacody-
namics of herbal medicines used for treatment of anxiety
disorders primarily involve modulation of neuronal commu-
nication, affecting neuroreceptor binding and activity [35],
or alteration of neurotransmitter synthesis and activity [36].
Anxiolytic nutraceuticals may have effects on the GABA
system either via inducing ionic channel transmission by
voltage-gated blockage, or through alteration of membrane
structures, GABA transaminase or glutamic acid decar-
boxylase inhibition, or less commonly via binding with
benzodiazepine receptor sites (e.g., GABA-A) [35]. Other
actions may involve dampening CNS activity, and regulating
or supporting the healthy function of the hypothalamic
pituitary adrenal-axis [80].
3.2.5. Conclusions. In summary, for reducing generalised
anxiety, evidence supports the use of Kava (although poten-
tial extremely rare hepatotoxicity needs to be considered),
while limited research points towards a beneficial effect
of Ginkgo, Passion flower, and Chamomile, multinutrient
formulations, Scullcap, Lemon balm, and Bacopa. Further
studies are needed to extend this research into clinical
cohorts. Although there appears to be growing support
for a general anxiolytic effect of aromatherapy, future
research is required to explore the effects on clinical
anxiety disorders. There is little support for the use of
St John’s wort for any anxiety disorder, while tentative
evidence supports inositol for PD and discourages its use in
OCD.
3.3. Physical Activity and Exercise
3.3.1. Overview. Physical inactivity is an established risk
factor for the development of many of health disorders,
including psychiatric illnesses [81]. For example, increased
rates of MDD were correlated with physical inactivity
in surveys of German [82] and Norwegian populations
[83]. Regular physical activity appears to reduce all-cause
mortality and is an established independent protective factor
for premature death [84, 85]. Mortality and morbidity aside,
regular physical activity has been repeatedly shown to be
associated with improved emotional wellbeing [86] and
inactivity with poorer emotional wellbeing [87].
3.3.2. Epidemiological Evidence. There is now considerable
evidence drawn from epidemiological surveys demonstrating
the association of regular physical activity with reduced
depressive and anxious symptoms [88, 89]. Utilising
cross-sectional data from the US national comorbidity
study of 8098 adults aged 15 to 54, Goodwin [90] revealed
regular physical activity as being associated with decreased
prevalence of current anxiety disorders, including panic
attacks (OR: 0.73), SP (OR: 0.63), specific phobia (OR: 0.78),
and agoraphobia (OR: 0.64). However, an inherent issue
with these cross-sectional studies is their inability to explain
the direction of relationship between physical activity
and anxiety. Regardless, mental disorders characterised by
anxiety and depression are associated with many symptoms
which may lead to reduced physical activity, such as fatigue,
poor motivation and social isolation [91].
3.3.3. Clinical Evidence. Few prospective observational stud-
ies have been conducted assessing the impact of physical
activity on anxiety disorders. Stro¨hle et al. [92] demon-
strated a lower incidence of some anxiety disorders, and
all anxiety disorders when grouped (OR: 0.70), as being
associated with regular physical activity in a sample of
2548 adolescents and young adults. In a Swedish cohort
prospectively followed for 2 years, moderate to vigorous
physical activity (defined as >2 hours of activities per week,
including aerobics, dancing, swimming, playing football, or
gardening) was significantly associated with fewer symptoms
of anxiety on the HADS (adjusted RR: 0.56) [93]. In
this study, the association between physical activity and
depression was of greater magnitude than with anxiety;
a finding consistent with previous studies in which self
reported depression rates (but not anxiety) were associated
with less physical activity [94, 95]. Prescriptive exercise has
demonstrated efficacy as a treatment strategy for anxiety
symptoms. In a recent metaanalysis, exercise as a therapeutic
intervention was found to be as effective as psychotherapy,
and nearly as effective as pharmacotherapy, for the treatment
of self-reported anxiety symptoms [96]. The effect size of
exercise for reduction of anxiety symptoms (d = −0.48)
however appears smaller than the benefit observed in
RCTs of exercise therapy in clinical depression (d = 1.42)
[97].
In regards to prescriptive use of exercise in diagnosed
anxiety disorders, currently there is a surprising deficit of
robust studies. However, in PD, a study of 46 individu-
als suffering from moderate to severe PD reported that
patients who received structured aerobic exercise had signif-
icantly greater symptomatic improvement than patients who
received placebo, but less improvement than those receiving
clomipramine [98]. Further, aerobic exercise training was
not statistically superior to relaxation when combined with
either paroxetine or placebo in the treatment of patients
with PD [99]. Other available pilot studies of structured
exercise programs have demonstrated beneficial effects as
individual or adjunctive therapies in patients with PTSD
[100–102], SP [103] and OCD [104]. However, these studies
generally suffer from methodological issues including lack
of control groups and small sample sizes. As it stands,
little other RCT evidence exists supporting the efficacy
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of exercise in the treatment of clinical anxiety disorders,
although further evidence may soon become available [105,
106].
3.3.4. Mechanisms of Action. The therapeutic effect of
physical activity or exercise in reducing anxiety is likely
the result of complex interactions between developmental,
neurobiological, and psychological processes [107]. The neu-
robiological mechanisms underpinning the effect of physical
activity on anxiety are not yet fully elucidated, but potentially
involve modulating activity of 5-HT neurons in the dorsal
ralph nucleus (DRN), modulation of the autonomic nervous
system (ANS) and regulation of various neuroactive agents,
including brain derived neurotrophic factor [108] and
beta-endorphins [109], and atrial natriuretic peptide
[110]. Exercise appears to protect against stress-induced
sensitisation of 5-HT DRN neurons which are known to
exhibit afferent and efferent projections to cortical regions,
the amygdala, locus coeruleus (LC), and periaqueductal grey
matter, which are areas associated with fear, anxiety, and
mood regulation [111]. In addition, exercise is known to
produce an anti-inflammatory state [112] and potentially
increase production of brain antioxidants [113]. Inflamma-
tion and oxidative stress are both postulated to have roles
in the pathogenesis of numerous mental disorders including
major depression [114]. In PD, exercise may be beneficial
by inducing interoceptive cues that elicit anxiety, and by this
repeated exposure to those sensations may assist in training
the person to manage these symptoms [115]. Furthermore,
exercise may induce beneficial downregulation of 5-HT2C
receptors in sufferers of PD [116, 117]. It is possible these
factors interact in a complex fashion in exerting protective
effects on the tumescence of anxiety symptoms.
3.3.5. Clinical Recommendations. Current clinical practice
guidelines for the treatment of anxiety disorders including,
PD, [118] support regular physical activity (e.g., walking for
60 minutes or running 20–30 minutes at least four days per
week) as part of best-practice treatment. These recommen-
dations are the same as those for MDD [119]. This is prudent
given the high comorbidity between depression and anxiety.
Moreover, given the relationship between physical activity
and mental health appears to be complex [120], the input of
robust RCT evidence will assist in substantiating and refining
these recommendations. For example, some evidence
suggests exercise recommendations should differ between
men and women. In a survey assessing the relationship
between exercise intensity and mental health, the positive
effects of vigorous activity on anxiety symptoms found in
men were not replicated in women [120]. In contrast to men,
women appeared to benefit significantly from less intense
forms of exercise (e.g., walking), with benefits found in more
general domains (e.g., well-being and somatisation) and not
those directly related to depressive or anxiety symptoms.
3.3.6. Conclusions. The weight of evidence supports the
use of moderate graded exercise to reduce anxiety and
can be in most cases recommended after an appropriate
health assessment. While the evidence strongly supports PA
and exercise as an acute anxiolytic, the utility of exercise
as treatment for anxiety disorders would benefit from
rigorously controlled studies.
3.4. Meditation Techniques (Mindfulness, Yoga, Tai Chi)
3.4.1. Overview. The concept of meditation is varied, with
a key attribute of the practice involving “mindfulness,” com-
monly defined as the awareness which arises through “paying
attention in a particular way: on purpose, in the present
moment, and nonjudgmentally” [121]. The development
of mindfulness has its origins in the spiritual tradition of
Buddhism, which dates back over 2,500 years. Over the past
60 years, ever since the advent of Buddhism in theWest, there
has been growing interest in the relationship between mind-
fulness, meditation, and mental health. In regards to anxiety
disorders, a growing body of empirical evidence exists. The
use of meditation as a Western behavioral intervention
was pioneered by Kabat-Zinn [122], who originally investi-
gated structured mindfulness training for the treatment of
chronic pain. The training program has become known as
Mindfulness-Based Stress Reduction (MBSR). MBSR is an
8–10 week structured program which involves (i) training in
mindfulness meditation practice, (ii) mindful awareness, for
example, during yoga postures, and (iii) mindfulness during
stressful everyday situations and social interaction. The typi-
cal MBSR course involves weekly group meetings, a one-day
workshop, and daily individual practice at home [123]. Over
the past 30 years, the MBSR technique has been investigated
in relation to a number of physical and mental illnesses, with
a moderate clinical effect being reported in relation to the
effect of MBSR on general mental health [123]. There is also
evidence to suggest that amongst the general population, the
MBSR technique may bring about a reduction in trait and
state anxiety and symptoms [124, 125]. A number of mind-
fulness techniques in the context of adaptations of CBT have
also been developed, includingMindfulness-Based Cognitive
Therapy (MBCT) [126], Dialectical Behavior Therapy (DBT)
[127], and Acceptance and Commitment Therapy (ACT)
[128]. However, due to the vast quanta of data in the area, the
focus of the current section will be on formal mindfulness
meditation techniques rather than obscure techniques, or
specific mindfulness approaches to CBT.
3.4.2. Clinical Evidence. Kabat-Zinn et al. [129] first inves-
tigated the efficacy of an 8-week MBSR program on anxiety
scores in 22 patients who met DSM-IIIR diagnostic criteria
for GAD or PD, as well as 58 “non-study” participants who
did notmeet formal criteria for an anxiety disorder yet scored
above the 70th percentile on the Symptom Check List-90
Revised (SCL-90-R). At the end of the treatment period, as
well as at 3-month followup, the number of patients expe-
riencing panic symptoms (measured by the Hamilton Panic
Score), was found to be significantly reduced, together with
overall symptoms of anxiety. In a followup study, 18 of the
original patients in addition to 39 of the larger study compar-
ison cohort we assessed byMiller [130] in order to determine
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if the improvements in anxiety symptoms were maintained
at 3 years. In the 18 original patients, posttreatment improve-
ments in theHamilton Panic Score, as well as the number and
severity of panic attacks were maintained at 3-year followup,
together with improvements on anxiety outcome measures.
As an adjunct to pharmacotherapy with benzodiazepines
or SSRIs, Lee et al. [131] investigated the efficacy of an 8-
week variant of the MBSR program in ameliorating anxiety
symptom severity in 41 patients who fulfilled DSM-IV
diagnostic criteria for either GAD or PD. Twenty one patients
were assigned to the MBSR group while the remaining 20
were assigned to an active control group in which they were
educated about the biological aspects of anxiety disorders
for one hour per week. In comparison to the education
group, the MBSR group displayed significant improvement
in anxiety symptoms on a range of outcome measures, such
as the HAM-A. Koszycki et al. [132] conducted a study which
directly compared the efficacy of an 8-week course in MBSR
with 12-weeks of group CBT in 53 patients with chronic SP.
Participants in both treatment groups were found to improve
significantly over the course of treatments, however, both
patient and clinician-rated measures of social anxiety were
found to be significantly lower in the CBT group in com-
parison to the MBSR group at endpoint. The response and
remission rates were also found to be significantly higher for
the CBT group in comparison to the MBSR group, although
the reported response rate of 45% for the completer sample
in the MBSR group is encouraging [132]. In a more recent
study Vøllestad et al. [133] investigated the efficacy of 8-week
MBSR in reducing anxiety amongst 39 patients with PD, SP,
or GAD, in comparison to a wait list control group of 37
participants. A significant difference between treatments in
favor of MBSR was found on the primary anxiety outcome.
Further, all treatment gains were found to be maintained at
6-month followup in the anxiety disorders group [133].
It has been argued that mindfulness practice may be of
some benefit in OCD [134]. However, there is a scarcity
of empirical research to date to investigate the efficacy of
mindfulness interventions for OCD, despite the fact that
some clinicians have claimed a degree of success using mind-
fulness approaches with their patients [134, 135]. A small
pilot study by Hanstede et al. [136] investigated the efficacy
of eight meditation group meetings (similar to MBSR) with
participants experiencingOCD symptoms; eight participants
were assigned to the mindfulness training while nine par-
ticipants were assigned to a waiting-list control group. The
mindfulness intervention was found to significantly reduce
OCD symptoms by enhancing the mental ability of “letting
go”. However, in the absence of a formal diagnosis of OCD
and a broadly recognised outcome measure it is difficult to
draw firm conclusions from this study.
3.4.3. Mechanisms of Action. A number of mechanisms
have been proposed whereby meditation and mindful-
ness techniques may ameliorate anxiety symptoms. First,
through meditation training physiological arousal or nega-
tive thoughts may become viewed increasingly as transient
events that come and go, decreasing the propensity of these
thoughts to trigger secondary reactions that increase subjec-
tive distress [137]. Second, meditation has been proposed
as a form of gradual exposure therapy, whereby prolonged
exposure to anxiety-provoking thoughts and images may
foster habituation [138, 139]. In this regard, Rapgay et
al. [140] argue that “classical mindfulness,” with a greater
emphasis on concentration to acquire direct experience, may
be more effective for the treatment of GAD than MBSR
because it involves greater exposure and habituation to
threatening stimuli, rather than discriminate analysis.
The benefits of meditation and mindfulness are also
now beginning to be understood at a neurobiological level.
Neuroimaging studies have provided evidence to suggest that
regular meditation is associated with a number of changes to
gray matter morphology using magnetic resonance imaging
(MRI). A study by Lazar et al. [141] reported that regular
insight meditation practice was found to be associated with
increased cortical thickness in a number of brain regions
associated with attention, such as the prefrontal cortex
and right anterior insula. Differences in prefrontal cortical
thickness were also found to be more pronounced in older
participants, which the authors interpreted as evidence that
meditation may offset decline in cortical thickness associated
with aging [141]. A number of other meditation practices
have also been investigated, with the hippocampus and
the right anterior insula found to be the most consistently
implicated regions for group differences [142]. Finally, there
is emerging direct evidence suggesting meditation may also
influence neurotransmitter release, with intriguing research
by Yu et al.[143] reporting that 20 minutes of focused
attention on breathing movements in the lower abdomen is
associated with significantly increased levels of oxygenated
haemoglobin in the anterior PFC, as measured by near-
infrared spectroscopy, as well a significant increase in whole
blood serotonin (5-HT) levels at 5 minutes and 30 minutes
after meditation [143].
3.4.4. Yoga and Tai Chi. Yoga and Tai chi are mind-body
practices that both have a long standing history of use. Yoga
is generally defined as a practice which consists of three
components: gentle stretching, exercises for breath control,
and meditation as a mind-body intervention [144]. Tai chi is
practiced in China as both a form of exercise and as a martial
art and involves moving from a standing position through a
series of postures like a choreographed dance. Sequences of
postures are known as “forms”, which require considerable
time and concentration to master [145].
In a systematic review of yoga for anxiety, Kirkwood et
al. [144] assessed eight studies for evidence of efficacy in the
amelioration of anxiety. Positive results were reported for the
effects of yoga treatments of durations up to three months,
although many of the studies suffered from methodological
limitations such as inadequate randomisation and high
dropout rates. Firm conclusions were also hindered by the
fact that there was a large diversity in the conditions studied,
including OCD, examination anxiety, snake phobia, and the
outdated diagnoses of anxiety neurosis and psychoneurosis
[144]. It is interesting to note that the most rigorously
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conducted study was in 22 adults with OCD, as diagnosed
by DSM-III-R. In this small study, three months of yoga
treatment was found to provide a significantly greater
reduction on the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS) and SCL-90-R at endpoint in comparison to
the relaxation response and mindfulness meditation control
group [146].
A recent systematic review of the effects of Tai chi on
psychological health and well-being was conducted by Wang
et al. [147]. While not relating directly to clinically diagnosed
anxiety disorders per se, the authors identified two RCTs
and six nonrandomised studies which reported Tai chi to
be associated with a significant reduction in anxiety when
practiced two to four times a week (30 to 60 minutes/time)
for five to 24 weeks. The overall effect size (Hedge’s g)
associated with reduction in anxiety symptoms between
groups was reported to be 0.66. However, it should be
noted that the 359 participants included in the metaanalysis
presented with a diverse range of health conditions. While
these preliminary findings are intriguing, further research
using individuals with formally diagnosed anxiety disorders
is required in order to properly test for the efficacy of Tai
chi in ameliorating anxiety in clinical populations. In regards
to the putative mechanisms of action of yoga and Tai chi
in reducing anxiety, further investigation is also required in
order to properly differentiate the effects of these meditative
exercise practices compared to normal physical activity or
other relaxation techniques.
3.4.5. Conclusions. In summary, while research into the
effectiveness of meditative techniques in the treatment of
anxiety is still in its infancy, a number of studies in clinical
populations have provided encouraging preliminary data of
a potential benefit for MBSR technique in GAD, SP and PD,
and insufficient but encouraging evidence for yoga and Tai
chi for the treatment of general anxiety. However, for OCD,
it is difficult at this stage to properly gauge the efficacy of
these techniques due to the scarcity of current research using
mindfulness interventions.
3.5. Diet and Nutrition
3.5.1. Overview. Public health and governmental agencies
support a balanced diet low in processed foods and rich
in fruits, vegetables, whole grains, legumes, fish, and lean
meats as part of a healthy lifestyle [148]. Such a diet reduces
the risk of developing numerous medical disorders including
cardiovascular disease [149] and some cancers [150]. There
is now emerging evidence that diet also affects our mental
health, although the relationship appears to be complex
and bidirectional. Many would recognise that changes in
stress levels influence our dietary choices. In a study of self
reported eating behavior, Oliver and Wardle [151] noted
that although people differentially increase or decrease their
food intake when anxious and stressed, the choice of food
appears to consistently move away from normal meal-
type foods toward high fat, high palatable snacks. This
finding appears independent of gender or dieting status.
Such changes in stress induced dietary choices have been
extensively replicated [152]. However, this phenomenon
may not necessarily extend to people with chronic mental
disorders, such as MDD, as some may in fact better their diet
in an attempt to improve their mental health [153].
3.5.2. Epidemiological Evidence. Research into the role of diet
on mental health is still developing and few studies have
assessed this in anxiety-disordered populations. However,
literature reporting on the relationships between diet quality
and anxiety in population-based observational studies does
provide some insight. The first study to examine the
association between whole diet and clinical anxiety and
depressive illnesses was conducted in population-based sam-
ple of Australian women [153]. In this cross-sectional study,
women scoring higher on a “traditional” (healthy) dietary
pattern, comprising fruits, vegetables, wholegrains and lean
red meats, were less likely to have either an anxiety disorder
or MDD or dysthymia, assessed using a gold-standard
clinical interview. In this study, higher scores on a “Western”
(unhealthy) dietary pattern were associated with an increased
likelihood of depressive illness (OR: 1.38), but not anxiety
disorders. Similarly, in a cross-sectional analysis of a large
sample of middle-aged and elderly adults from Norway,
higher scores on an a priori diet quality score (compris-
ing vegetables, fruits, wholegrains, fish, and nonprocessed
meats) was found to be associated with reduced likelihood
of anxiety, measured on the HADS, in women (OR: 0.77),
and with reduced case-level depression in both men (OR:
0.83) and women, (OR: 0.71) before and after adjustment
for age, income, education, physical activity, smoking, and
alcohol consumption [154]. Conversely, consumption of a
“Western diet” (comprised of processed meats, pizza, salty
snacks, chocolates, sugars and sweets, soft drinks, margarine,
French fries, beer, coffee, cake, and ice cream) was associated
with significantly increased likelihood of anxiety, but not
depression, in men and women [154].
3.5.3. Mechanisms of Action. Although incompletely under-
stood, numerous studies provide some insight into the
mechanisms of the diet-anxiety interaction. As in humans,
increased stress in rats is associated with increased con-
sumption of highly palatable foods [155]. In the “drive
induction hypothesis” [156] this association is thought to
result from the effects of stress induced elevated glucocor-
ticoids (GC). Elevated GC are hypothesised to cross the
blood brain barrier and act directly on central pathways
mediating appetite behaviors (increasing motivation for
consumption). As this occurs, peripheral elevations of GC
facilitate increased negative feedback blunting central stress
responses. There is some evidence that intake of high
fat diets may provide selective protection against certain
anxiety states. In a study of rats fed a chronic high fat
diet, certain antidepressant-sensitive anxiety behaviors (e.g.,
from the forced swim test), and those provoked by the
light-dark box test, appeared reduced but anhedonic and
social avoidance behaviors remained unchanged [157]. The
short-term protective effects of highly palatable food may
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however lead to adverse long-term consequences. Recent
evidence has demonstrated that intake of highly palatable
foods is associated with increased production of reactive
oxygen species (ROS) [158]. Increased ROS production and
subsequent oxidative stress are postulated to contribute to
the development of anxiety disorders [159].
In respect to which nutrients from the diet may have
an anxiolytic effect, numerous studies have identified the
relationship between omega-3 and omega-6 fatty acids
and depression and anxiety. Decreased omega-3 and an
increased omega-6 to omega 3 ratio are associated with
an increased rate of depression in some studies [160,
161]. Similarly, decreased levels of omega-3 have been
associated with increased SP [162], while low levels of
DHA consumption exhibited a cross sectional relationship
with anxiety disorders in a large population cohort (Jacka
et al., 2012, unpublished data). In one recently reported
RCT, supplemental omega-3 was compared to placebo in
a group of medical students on depressive and anxiety
symptoms and levels of various inflammatory mediators
[163]. The students who received omega-3 supplementation
showed a 14% reduction in lipopolysaccharide stimulated
interleukin 6 (IL-6) and 20% reduction in anxiety symptoms
measured on the BAI. Interestingly, no effect was found
on depressive symptoms. Other dietary elements including
magnesium [164] and zinc [165] also appear related to
mental health status [166], and have preclinical animal
model evidence of anxiolytic and antidepressant effects [167,
168], however, empirical studies have not yet confirmed
any therapy effect of supplementation for anxiety disor-
ders.
3.5.4. Conclusions. While prospective studies are currently
limited, the emerging body of evidence encourages the
recommendation for bettering general mental health by
adopting a diet rich in lean protein, complex carbohydrates,
fruit and vegetables, with adequate omega 3; and low in
refined carbohydrates, saturated fats, and processed foods.
At present however, no clinical trial has been conducted
assessing the effect of a healthy diet versus a suitable control,
to establish whether dietary modification is beneficial in
treating anxiety disorders.
3.6. Substance Use/Misuse (Alcohol, Caffeine, Nicotine)
3.6.1. Overview. There is a solid body of evidence linking
lifestyle factors with depression. Modifiable factors impact-
ing on risk, course and outcome include alcohol, smoking,
recreational drugs, diet, and exercise. The same is true of
anxiety, although the body of clinical and epidemiological
data is larger in depression than in anxiety. There is however
a well-replicated relationship between anxiety disorders and
substance use. The use of all drugs of dependence (smoking,
alcohol, opiates) result in an enduring withdrawal state
interrupted by periodic intoxications. This is mediated by
the homeostatic adaptation to the persistent presence of
exogenous drugs. Substance abuse can also be seen as
a maladaptive coping strategy that procrastinates having
to manage the source of the dysphoria or anxiety and
undermines the development of adaptive strategies [169].
Substance use may mitigate anxiety symptoms in the short-
term. However, the use of tobacco and/or alcohol predisposes
people to the development of anxiety over time by producing
chronic withdrawal symptoms, reduced health quality, and
the possible precipitation of somatic or emotional symptoms
that maintain anxiety [170]. It is however, important to note
that not all individuals who have anxiety abuse substances;
other vulnerability factors, including personality, social
support, development and attachment, and genetics, mediate
this relationship. From a management perspective, anxiety
and concurrent substance abuse require integrated manage-
ment.While there are few trials formanagement of comorbid
substance use and anxiety [171], CBT, for example, has been
shown to be useful for substance abuse related anxiety [172].
3.6.2. Nicotine. Smoking is more common in those with
anxiety, particularly PD [173], and those with anxiety smoke
for longer periods, increasing the predisposition to smoking-
related complications. In the Australian Survey of Mental
Health and Wellbeing [174], over a fifth of adult smokers
reported 12-month anxiety disorders. There was a dose
dependant relationship between smoking rates and illness
severity, however, smoking rates were doubled even among
those with mild anxiety. Complicating management, smok-
ers with anxiety were less likely to attempt cessation. Smok-
ing cessation specifically for the treatment of anxiety has not
been formally examined in rigorous clinical trials, however,
anxiety is noted to increase withdrawal symptoms in the
context of smoking cessation [175]. People with anxiety or
depression are as likely as those without these symptoms
to want to stop smoking, but are less likely to make a
quit attempt [176]. Smoking cessation, importantly, does
not appear to increase anxiety or depression after quitting
and might reduce symptoms, although data are inconsistent
[177–179]. Cigarettes modulate perception of emotional and
somatic states via postsynaptic nicotinic receptor agonism,
and ultimately downregulate dopamine D2 receptors in the
nucleus accumbens, the site of the reward system [180].
3.6.3. Caffeine. Caffeine is perhaps the most commonly used
psychoactive substance. It is perceived to increase attention,
alertness, cognition, and mood, with some individuals with
dysphoric mood being predisposed to use it more heavily,
tapping into its mood-elevating potential (via activation
of noradrenergic and dopaminergic pathways) [181]. As a
common consequence of overuse, this psychostimulant may
increase arousal and subsequent anxiety and insomnia [182].
It additionally carries the potential for mild drug depen-
dence. Those with anxiety disorders, including PD and SP,
are especially sensitive to the anxiogenic effects of caffeine.
The effects of oral administration of caffeine (10mg/kg) in
17 healthy subjects and 21 patients meeting DSM-III criteria
for agoraphobia with panic attacks or panic disorder found
caffeine produced significantly greater increases in subject-
rated anxiety, nervousness, fear, palpitations, restlessness,
and tremors compared with healthy controls [183]. Caffeine
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also increased plasma cortisol levels in both the anxious and
healthy groups. Caffeine modulates the adenosine system,
while the anxiogenic potential of caffeine is influenced in
part by polymorphisms of the A2A receptor [184].While evi-
dence supports the avoidance of caffeine in anxiety disorders,
a contrary therapeutic approach involves using caffeine to
provoke panic attacks (similar to inducement from exercise),
in order to train the person via a caffeine “challenge test” to
manage these anxiogenic symptoms [185].While prospective
studies have not evaluated the effect of caffeine reduc-
tion/avoidance in people with anxiety disorders, pragmati-
cally, those with anxiety symptoms who have large amounts
of caffeine should be counselled to moderate their intake.
3.6.4. Alcohol. Approximately half of people receiving treat-
ment for an alcohol misuse or abuse disorder also suffer with
an anxiety or depressive disorder [186]. Alcohol misuse or
abuse may prompt acute withdrawal anxiety, via an increased
level of stimulatory glutamate, and a desensitization of
GABA pathways [187]. Furthermore, long-term alcohol use
may reduce levels or critical nutrients required for neuro-
logical function, such as B vitamins [188]. A metaanalysis of
RCTs that reviewed additional focused treatment of alcohol
use disorder in patients with comorbid anxiety disorders
(GAD, PD, SP) found a significant effect for both drug and
CBT interventions for reducing anxiety, with a pooled effect
size (d) of 0.52 [189]. This effect was also significant for
addressing alcohol reduction with an effect size of 0.27.
As anxiety disorders are also highly comorbid with
alcohol abuse and dependence [190], there appears to be a
bidirectional relationship between alcohol use and anxiety,
such that each disorder can maintain or exacerbate the other.
This relationship appears most relevant in young people,
the age of genesis of most adult patterns of illness [191].
The coaggregation of these disorders has a range of potential
explanations. The “self-medication” hypothesis suggests that
people use alcohol to reduce anxiety, emotional distress or
dysphoric affective symptoms [192], and thus patients with
affective or anxiety disorders should be screened for alcohol
misuse.
3.6.5. Conclusions. While the link between substance misuse
and generalised anxiety or anxiety disorders has been
established, further therapeutic treatment approaches are
required. At present, CAM treatments such as herbal
medicines or acupuncture appear to not have sufficiently
supportive evidence in addressing alcohol misuse or abuse
disorder [193, 194]. Regardless, it is likely these may have
a role as “supportive” interventions rather than treatments
per se. An erudite clinical position is to encourage with-
drawal/reduction of alcohol, nicotine and caffeine with
appropriate health professional supervision.
4. Discussion
Across the breadth of the literature reviewed, many non-
conventional interventions provide promise for assisting
in reducing anxiety and treating anxiety disorders. Of the
nutraceuticals reviewed, the only intervention currently
supported by evidence is Kava, while preliminary evidence
is extended for a range of nutraceuticals. Currently, of
the CAM modalities reviewed, naturopathic medicine has
one supportive un-replicated study, while acupuncture and
massage have preliminary evidence, although the area suffers
from poor methodology and the common use of nonclinical
samples. Present evidence does not support homeopathy
as a treatment to reduce anxiety. This review suggests
that supportive evidence exists for the recommendation of
lifestyle modifications including moderate graded exercise,
mindfulness meditation techniques, and caffeine minimisa-
tion. While no prospective studies support the use of dietary
modification as an intervention, the epidemiological evi-
dence supports dietary improvement. Restriction of lifestyle
vices such as alcohol and nicotine appears to be beneficial in
reducing anxiety, although more data are needed, specifically
the study of assisted substance-withdrawal programs on
anxiety disorders, and controlled prospective studies. One
consideration regarding the impact of lifestyle modification
in addressing anxiety disorders that is challenging to tease
apart scientifically, is the effect that by altering behavior (e.g.,
a new dietary pattern or exercise), this will usually cause a
range of psychosocial changes that may also be therapeutic.
Currently, a notable gap in the literature concerns the
deficit in our understanding of the impact of healthy dietary
change on anxiety disorders. Surprisingly, to date there have
been no quality RCTs investigating the impact of whole
dietary improvement in those with an anxiety or depressive
disorders. As such, further such investigations would assist in
making specific dietary recommendations in mental health
treatment. Regarding MBSR as a treatment, future research
would benefit from the following guidelines; (i) the effects
of MBSR needs to be clearly differentiated according to the
varied anxiety disorders, (ii) greater effort needs to be made
to include a suitable control group, and (iii) there needs
to be stricter adherence to the standardised MBSR protocol
together with more detailed documentation of treatment
compliance. It would be valuable to also consider the efficacy
of longer term meditation and mindfulness techniques in
the treatment of anxiety and the prevention of relapse.
Given that these techniques have traditionally been used as
a daily practice over the course of the lifetime, it would be
informative to conduct studies of longer duration.
Advice for clinicians wishing to institute lifestyle, self-
help or CAM interventions in patients with anxiety disorders
centers initially upon considerations such as their patients’
diagnosis and state of distress, current medication, psychoso-
cial factors, personal preferences, and financial resources.
Specific considerations include assessment of a patient’s
physical health if prescribing exercise, as is referral for appro-
priate assessment. Dietary modifications should be delicately
instituted as patients may find change difficult if using food
as a psychological crutch. Referral to dieticians, often acces-
sible through the public system, may be of benefit to some.
Considerations regarding nutraceuticals include potential
interactions with medications, thus pharmacokinetic and
pharmacodynamic elements need to be assessed. Cost of
these supplements is also a factor, with some high-quality
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standardised nutraceuticals being expensive. CAM research
needs to be increased, as currently many nutraceuticals
and modalities have either unreplicated studies, or studies
using poor methodology. Reduction of vices such as alcohol,
caffeine and nicotine may initially exacerbate anxiety and
should therefore be undertaken in a graded and supported
fashion.
Limitations to this metareview include a nonsystematic
approach to data inclusion. Regardless, a narrative inclusive
methodology was employed specifically to cover both an
over-arching cross section of the literature, and to provide
a clinically relevant narrative for readers. Only English
language studies were included, which may have discounted
other important evidence. A final limitation is that, as the
area covered was very broad, an intricate written analysis
of the data was not possible due to publication space
restrictions.
In summary, a range of CAM, lifestyle and self-help
interventions hold promise as adjunctive approaches to
psychological and pharmacological interventions to reduce
anxiety and treat anxiety disorders. Future focus can involve
the use of integrated approaches combining evidence-based
approaches to address lifestyle, psychological, biological, and
sociological determinants of these disorders.
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